Russell Investments Group Ltd. boosted its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 81.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 170,243 shares of the company’s stock after purchasing an additional 76,350 shares during the quarter. Russell Investments Group Ltd.’s holdings in Moderna were worth $7,019,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of the stock. Wilmington Savings Fund Society FSB increased its stake in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares in the last quarter. Venturi Wealth Management LLC raised its position in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares during the period. Compass Planning Associates Inc acquired a new stake in Moderna in the 4th quarter valued at $37,000. Crowley Wealth Management Inc. bought a new stake in Moderna during the 4th quarter valued at $41,000. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after buying an additional 389 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.
Moderna Price Performance
MRNA stock opened at $26.20 on Monday. The firm has a 50 day simple moving average of $31.56 and a two-hundred day simple moving average of $40.84. The stock has a market cap of $10.13 billion, a PE ratio of -2.82 and a beta of 2.23. Moderna, Inc. has a one year low of $23.15 and a one year high of $170.47.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on Moderna
About Moderna
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Featured Stories
- Five stocks we like better than Moderna
- Stock Analyst Ratings and Canadian Analyst Ratings
- Is McDonald’s Stock Serving a Value Meal to Investors?
- What Are Dividends? Buy the Best Dividend Stocks
- Walgreens Comeback? Private Equity Circling for a Buyout
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Coca-Cola Stock Looks Refreshing After the Relief Rally
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.